MAIA Biotechnology, Inc. financial data

Symbol
MAIA on NYSE
Industry
Pharmaceutical Preparations
Location
444 West Lake Street, Suite 1700, Chicago, IL
State of incorporation
DE
Fiscal year end
December 31
Latest financial report
10-Q - Q3 2024 - Nov 12, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 221 % -12.5%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 25.3M shares +78.2%
Common Stock, Shares, Outstanding 24M shares +74.2%
Entity Public Float 22.5M USD
Common Stock, Value, Issued 2.4K USD +74.1%
Weighted Average Number of Shares Outstanding, Basic 23.9M shares +74.7%
Weighted Average Number of Shares Outstanding, Diluted 23.9M shares +74.7%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense 10.8M USD +9.9%
General and Administrative Expense 7.57M USD -7.77%
Operating Income (Loss) -18.3M USD -1.84%
Income Tax Expense (Benefit) 0 USD
Earnings Per Share, Basic -1.37 USD/shares +6.16%
Earnings Per Share, Diluted -1.37 USD/shares +6.16%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 0 USD
Assets, Current 9.24M USD +39.3%
Other Assets, Noncurrent 2.8K USD 0%
Assets 9.24M USD +32%
Accounts Payable, Current 1.15M USD -6.04%
Accrued Liabilities, Current 2.46M USD -16%
Liabilities, Current 3.61M USD -13%
Liabilities 7.62M USD +79.3%
Accumulated Other Comprehensive Income (Loss), Net of Tax -11.7K USD +73.3%
Retained Earnings (Accumulated Deficit) -83.7M USD -44.9%
Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest 1.62M USD -41.1%
Liabilities and Equity 9.24M USD +32%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -3.59M USD -6.73%
Net Cash Provided by (Used in) Financing Activities 4.72M USD
Common Stock, Shares Authorized 70M shares 0%
Common Stock, Shares, Issued 24M shares +74.2%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 1.12M USD
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 8.69M USD +42.4%
Deferred Tax Assets, Valuation Allowance 10.4M USD +66.5%
Deferred Tax Assets, Gross 10.4M USD +66.5%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -25.9M USD -46.8%
Deferred Tax Assets, Operating Loss Carryforwards 5.23M USD +58.6%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 30M shares 0%
Additional Paid in Capital 85.3M USD +40.9%
Preferred Stock, Shares Outstanding 0 shares
Share-based Payment Arrangement, Expense 2.58M USD +16.5%
Interest Expense 85 USD
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%